Abstract

Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti-influenza therapy. The 150-cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150-cavity based on the structure information of oseltamivir carboxylate (OC) in complex with NA. In this study, a series of C-5-NH2-acyl derivatives of OC containing the pyrazole moiety were synthesized. Several derivatives exhibited substantial inhibitory activity against NA. Moreover, in silico ADME evaluation indicated that the derivatives were drug-like with higher oral absorption rates and greater cell permeability than OC. Additionally, molecular docking studies revealed that the derivatives interacted with both the NA enzyme active site and 150-cavity as expected. The results provided useful information for further structural optimization of OC.

Highlights

  • Amine derivatives of for probing the Results indicated that the introamine derivatives of oseltamivir carboxylate (OC) for probing the 150-cavity [17]

  • In silico ADME prediction suggest that the four compounds have drug-like pharmacokinetic properties

  • Parameters for oral absorption and cell permeability indicated the prospect of direct oral administration of the derivatives, such as 6i, 12c, 24b, and 26b

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Russel et al disclosed that group-1 neuraminidases a 150-cavity so-called adjacent to theirobservations, active sites, suggests a new binding pocket forcontain drug design. Adjacent to their active sites, which suggests a new binding pocket for drug design. 150-cavity adjacent to their active sites, which suggests a new binding pocket for drug. Was alsothat reported thatcould be induced to anposition open position binding of oseltamivir carboxylate to NA [13]. Reported as binders, including second amine derivatives been reportedbinders, as150-cavity. These derivatives inhibited at the nM level, and most of them possessed the selectivity.

Representative modified
2.1.Design
Synthetic route of compounds
Neuraminidase Enzyme Inhibitory Assay
Inhibitory rates of designed compounds against
In SilicoTo
In Silico ADME Prediction
Molecular Docking Studies
Methods
General Procedures for the Synthesis of Compounds 3a–k
General Procedure for the Synthesis of Compounds 4a–k
General Procedure for the Synthesis of Compounds 5a–k
General Procedure for the Synthesis of Compounds 6a–k
3.2.17. General Procedure for the Synthesis of Compounds 9a–f
3.2.20. General Procedure for the Synthesis of Compounds 12a–f
3.2.27. General Procedure for the Synthesis of Compounds 13a–c
3.2.30. General Procedure for the Synthesis of Compounds 16a–c
3.2.34. General Procedure for the Synthesis of Compounds 19a–e and 20a–d
3.2.37. General Procedure for the Synthesis of Compounds 24a–e and 26a–d
In Silico Studies
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call